Complete financial analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynerba Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lizhi Inc. (LIZI) Income Statement Analysis – Financial Results
- First Solar, Inc. (FSLR.SW) Income Statement Analysis – Financial Results
- Gilat Satellite Networks Ltd. (GILT.TA) Income Statement Analysis – Financial Results
- Forward Science Corp. (7530.TWO) Income Statement Analysis – Financial Results
- Kumho Petrochemical Co., Ltd. (011785.KS) Income Statement Analysis – Financial Results
Zynerba Pharmaceuticals, Inc. (ZYNE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zynerba.com
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.10M | 21.42M | 35.65M | 20.38M | 27.25M | 22.81M | 16.78M | 7.45M | 2.40M | 1.13M |
| General & Administrative | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Cost & Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Interest Income | 846.86K | 21.05K | 243.99K | 1.52M | 961.32K | 519.55K | 80.22K | 0.00 | 0.00 | 0.00 |
| Interest Expense | -215.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 631.13K | 559.68K | -481.72K | 145.91K | 99.57K | 94.21K | 75.30K | 26.03K | 27.06K | 49.39K |
| EBITDA | -34.62M | -36.21M | -52.06M | -34.17M | -40.40M | -32.82M | -23.21M | -12.51M | -5.64M | -585.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,422.28% | -456,747.03% | -316,123.92% | -4,483.73% | -696.37% | -61.98% |
| Operating Income | -35.25M | -36.77M | -52.06M | -34.32M | -40.40M | -32.82M | -23.21M | -12.53M | -5.67M | -634.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,974.22% | -452,731.16% | -320,105.21% | -4,493.07% | -699.71% | -67.21% |
| Total Other Income/Expenses | 215.73K | -538.63K | 725.71K | 1.38M | 486.66K | 810.71K | -208.42K | 7.35K | -1.84K | -2.35K |
| Income Before Tax | -35.04M | -37.31M | -51.34M | -32.94M | -39.91M | -32.01M | -23.42M | -12.52M | -5.67M | -636.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,980.00% | -4,490.43% | -699.94% | -67.46% |
| Income Tax Expense | -215.73K | 291.49K | -932.75K | -1.51M | 486.66K | -27.54K | -27.54K | 27.54K | 0.00 | 0.00 |
| Net Income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.39M | -12.55M | -5.67M | -636.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,600.10% | -4,500.30% | -699.94% | -67.46% |
| EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| Weighted Avg Shares Out | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
| Weighted Avg Shares Out (Dil) | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome (FXS)....
Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeting of the American College of Neuropsychopharmacology
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizona. The poster, titled 'An Open-Label Tolerability and Efficacy Study of ZYN002 (cannabidiol) Administered...
Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with a placebo in a recent Phase 3 trial. Results from the Phase 3 CONNECT-FX study of...
Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22q
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported it has further advanced its transdermal gel Zygel—receiving orphan drug designation from the European Commission (EC) for the gel's active ingredient to treat 22q11.2 deletion syndrome (22q). Zygel, which contains cannabidiol, was previously granted orphan...
Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter that revealed ample cash on hand, giving the company scope to fund pivotal trials of its flagship product...
Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zygel
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced that the US Patent and Trademark Office has issued Patent No. 11,458,109, titled "Treatment of 22q11.2 Deletion Syndrome With Cannabidiol," which includes claims directed to methods of treating one or more behavioral symptoms of...
Zynerba Pharma presents positive data from Phase 2 INSPIRE trial at NORD Rare Diseases and Orphan Products Breakthrough Summit
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington DC. The poster, titled ‘An Open-Label Tolerability...
Zynerba Pharmaceuticals receives new US patent for its cannabidiol formulated gel Zygel
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has boosted its international intellectual property (IP) portfolio, revealing it has been granted a new US patent for its cannabidiol-formulated gel Zygel. The US patent and trademark office issued the patent, which is entitled "Treatment of...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present...
Zynerba Pharmaceuticals presents positive data from phase 2 INSPIRE trial in 22q at the Society for the Study of Behavioural Phenotypes 24th International Research Symposium
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced an oral presentation at the Society for the Study of Behavioural Phenotypes' 24th International Research Symposium, being held in Oslo, Norway, from September 8 to 10. Helen (Honey) Heussler, an associate professor in the...
Source: https://incomestatements.info
Category: Stock Reports